3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Neuroendocrine Tumors
11
Adrenocortical Carcinoma
7
Thyroid Carcinoma, Anaplastic
5
Carcinoma, Neuroendocrine
4
Thyroid Neoplasms
3
Adrenal Cortex Neoplasms
3
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Small Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Vulvar Neoplasms
1
Vascular Neoplasms
1
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Thyroid cancer, Hurthle cell
1
Thyroid Cancer, Papillary
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Penile Neoplasms
1
Pathologic Processes
1
Parotid Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Paraganglioma
1
Neoplasms, Unknown Primary
1
Neoplasms, Germ Cell and Embryonal
1
Multiple Myeloma
1
Interventions
lutetium Lu 177 dotatate
8
lanreotide
4
copper dotatate CU-64
4
Octreotide
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
pasireotide
3
Magnetic Resonance Spectroscopy
3
Lutetium-177
3
Lutetium
3
gallium Ga 68 dotatate
2
amino-acid, glucose, and electrolyte solution
2
Temozolomide
2
Nivolumab
2
Irinotecan
2
Ga(III)-DOTATOC
2
Everolimus
2
Etoposide
2
Carboplatin
2
zimberelimab
1
regorafenib
1
pembrolizumab
1
irinotecan sucrosofate
1
folfirinox
1
famitinib
1
cabozantinib
1
arginyllysine
1
abemaciclib
1
X-Rays
1
Sunitinib
1
Somatostatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
pembrolizumab
×
Endocrine
×
Clear all
NCT03043664
2023-06-29
PLANET
Duke University
Phase 1/2
Completed
22 enrolled
12 charts